Changes in Cardiovascular Risk Factors and Health Care Expenditures Among Patients Prescribed Semaglutide
In this cohort study of adults prescribed semaglutide, initiation was associated with reductions in weight and cardiovascular risk factors but increases in health care expenditures, excluding semaglutide costs. These findings suggest potential clinical benefits in routine practice, while highlighting the need to evaluate the long-term impact of semaglutide on economic outcomes.
Authors
- Jason Abaluck (ORCID: https://orcid.org/0000-0002-0932-9369)
- Rohan Khera (ORCID: https://orcid.org/0000-0001-9467-6199)
- John E. Brush (ORCID: https://orcid.org/0000-0001-8192-494X)
- Chungsoo Kim (ORCID: https://orcid.org/0000-0003-1802-1777)
- Yuntian Liu (ORCID: https://orcid.org/0000-0001-6571-6112)
- Hua Xu (ORCID: https://orcid.org/0000-0002-5274-4672)
- Yuan Lu (ORCID: https://orcid.org/0000-0001-5264-2169)
- Harlan M. Krumholz (ORCID: https://orcid.org/0000-0003-2046-127X)
- Tedi Totojani
Institutions
- National Bureau of Economic Research (US)
- Yale New Haven Hospital (US)
- Yale University (US)
- Sentara College of Health Sciences (US)
- Yale New Haven Health System (US)
- Sentara Virginia Beach General Hospital (US)
- Old Dominion University (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-08-08
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.26013
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59
Funders
- Bristol-Myers Squibb
- Pfizer
- Yale University
- Novo Nordisk
- National Institutes of Health
- National Heart, Lung, and Blood Institute